If correct, this finding has major implications for the treatment of patients with HF, a large proportion of whom have a normal ejection fraction, as well as our understanding of the pathophysiology of this syndrome and how SGLT2 inhibitors exert their benefits in HF. This evidence concerns the gene SLC5A2 and hydrops fetalis.